Drugs / ADP101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05243719 | Mar 2022 → Feb 2024 | food allergy | Alladapt Immunotherapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04856865 | Apr 2021 → Nov 2022 | food allergy | Alladapt Immunotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05243719 ↗ |
| Route | Oral | “Participants received ADP101 at a starting dose of 5mg po daily” NCT04856865 ↗ |